Literature DB >> 26405155

Aggravated bone density decline following symptomatic osteonecrosis in children with acute lymphoblastic leukemia.

Marissa A H den Hoed1, Saskia M F Pluijm1, Mariël L te Winkel2, Hester A de Groot-Kruseman3, Martha Fiocco4, Peter Hoogerbrugge5, Jan A Leeuw6, Marrie C A Bruin7, Inge M van der Sluis2, Dorien Bresters8, Maarten H Lequin9, Jan C Roos10, Anjo J P Veerman11, Rob Pieters12, Marry M van den Heuvel-Eibrink13.   

Abstract

Osteonecrosis and decline of bone density are serious side effects during and after treatment of childhood acute lymphoblastic leukemia. It is unknown whether osteonecrosis and low bone density occur together in the same patients, or whether these two osteogenic side-effects can mutually influence each other's development. Bone density and the incidence of symptomatic osteonecrosis were prospectively assessed in a national cohort of 466 patients with acute lymphoblastic leukemia (4-18 years of age) who were treated according to the dexamethasone-based Dutch Child Oncology Group-ALL9 protocol. Bone mineral density of the lumbar spine (BMDLS) (n=466) and of the total body (BMDTB) (n=106) was measured by dual X-ray absorptiometry. Bone density was expressed as age- and gender-matched standard deviation scores. Thirty patients (6.4%) suffered from symptomatic osteonecrosis. At baseline, BMDLS and BMDTB did not differ between patients who did or did not develop osteonecrosis. At cessation of treatment, patients with osteonecrosis had lower mean BMDLS and BMDTB than patients without osteonecrosis (respectively, with osteonecrosis: -2.16 versus without osteonecrosis: -1.21, P<0.01 and with osteonecrosis: -1.73 versus without osteonecrosis: -0.57, P<0.01). Multivariate linear models showed that patients with osteonecrosis had steeper BMDLS and BMDTB declines during follow-up than patients without osteonecrosis (interaction group time, P<0.01 and P<0.01). We conclude that bone density status at the diagnosis of acute lymphoblastic leukemia does not seem to influence the occurrence of symptomatic osteonecrosis. Bone density declines from the time that osteonecrosis is diagnosed; this suggests that the already existing decrease in bone density during acute lymphoblastic leukemia therapy is further aggravated by factors such as restriction of weight-bearing activities and destruction of bone architecture due to osteonecrosis. Osteonecrosis can, therefore, be considered a risk factor for low bone density in children with acute lymphoblastic leukemia. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Year:  2015        PMID: 26405155      PMCID: PMC4666332          DOI: 10.3324/haematol.2015.125583

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  47 in total

Review 1.  Management of osteonecrosis in children and young adults with acute lymphoblastic leukaemia.

Authors:  Ajay Vora
Journal:  Br J Haematol       Date:  2011-09-21       Impact factor: 6.998

2.  Effect of swimming on bone metabolism in adolescents.

Authors:  Orhan Derman; Alphan Cinemre; Nuray Kanbur; Muhsin Doğan; Mustafa Kiliç; Erdem Karaduman
Journal:  Turk J Pediatr       Date:  2008 Mar-Apr       Impact factor: 0.552

3.  Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Pediatric Position Development Conference.

Authors:  Sanford Baim; Mary B Leonard; Maria-Luisa Bianchi; Didier B Hans; Heidi J Kalkwarf; Craig B Langman; Frank Rauch
Journal:  J Clin Densitom       Date:  2008 Jan-Mar       Impact factor: 2.617

Review 4.  Influence of sports participation on bone health in the young athlete: a review of the literature.

Authors:  Adam S Tenforde; Michael Fredericson
Journal:  PM R       Date:  2011-09       Impact factor: 2.298

5.  Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group.

Authors:  L A Mattano; H N Sather; M E Trigg; J B Nachman
Journal:  J Clin Oncol       Date:  2000-09-15       Impact factor: 44.544

6.  Inhibition of cortical and trabecular bone formation in the long bones of immobilized monkeys.

Authors:  T J Wronski; E R Morey
Journal:  Clin Orthop Relat Res       Date:  1983-12       Impact factor: 4.176

7.  Bone and mineral abnormalities in childhood acute lymphoblastic leukemia: influence of disease, drugs and nutrition.

Authors:  S A Atkinson; J M Halton; C Bradley; B Wu; R D Barr
Journal:  Int J Cancer Suppl       Date:  1998

8.  The effects of twelve weeks of bed rest on bone histology, biochemical markers of bone turnover, and calcium homeostasis in eleven normal subjects.

Authors:  J E Zerwekh; L A Ruml; F Gottschalk; C Y Pak
Journal:  J Bone Miner Res       Date:  1998-10       Impact factor: 6.741

9.  Two-week longitudinal survey of bone architecture alteration in the hindlimb-unloaded rat model of bone loss: sex differences.

Authors:  Valentin David; Marie-Hélène Lafage-Proust; Norbert Laroche; Alexandre Christian; Peter Ruegsegger; Laurence Vico
Journal:  Am J Physiol Endocrinol Metab       Date:  2006-03       Impact factor: 4.310

10.  Prospective bone ultrasound patterns during childhood acute lymphoblastic leukemia treatment.

Authors:  Alessandro Mussa; Nicoletta Bertorello; Francesco Porta; Chiara Galletto; Mario Guido Nicolosi; Rosaria Manicone; Andrea Corrias; Franca Fagioli
Journal:  Bone       Date:  2010-01-04       Impact factor: 4.398

View more
  8 in total

Review 1.  Osteonecrosis in children with acute lymphoblastic leukemia.

Authors:  Marina Kunstreich; Sebastian Kummer; Hans-Juergen Laws; Arndt Borkhardt; Michaela Kuhlen
Journal:  Haematologica       Date:  2016-10-14       Impact factor: 9.941

2.  Genetic Biomarkers to Identify the Risk of Osteonecrosis in Children with Acute Lymphoblastic Leukemia.

Authors:  Marissa A H den Hoed; Saskia M F Pluijm; André G Uitterlinden; Rob Pieters; Marry M van den Heuvel-Eibrink
Journal:  Mol Diagn Ther       Date:  2016-12       Impact factor: 4.074

3.  Incidence of hip and knee osteonecrosis and their associations with bone mineral density in children with acute lymphoblastic leukaemia.

Authors:  Hiroto Inaba; Xueyuan Cao; Jennifer Y Chang; Seth E Karol; John C Panetta; Kirsten K Ness; Cheng Cheng; Ching-Hon Pui; Mary V Relling; Sue C Kaste
Journal:  Br J Haematol       Date:  2020-03-24       Impact factor: 6.998

Review 4.  The genetics and molecular biology of T-ALL.

Authors:  Tiziana Girardi; Carmen Vicente; Jan Cools; Kim De Keersmaecker
Journal:  Blood       Date:  2017-01-23       Impact factor: 22.113

Review 5.  MicroRNA expression and activity in T-cell acute lymphoblastic leukemia.

Authors:  Fang Ye
Journal:  Oncotarget       Date:  2017-12-20

Review 6.  Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy.

Authors:  Kjeld Schmiegelow; Klaus Müller; Signe Sloth Mogensen; Pernille Rudebeck Mogensen; Benjamin Ole Wolthers; Ulrik Kristoffer Stoltze; Ruta Tuckuviene; Thomas Frandsen
Journal:  F1000Res       Date:  2017-04-07

Review 7.  Osteonecrosis in Adults With Acute Lymphoblastic Leukemia: An Unmet Clinical Need.

Authors:  Michaela Kuhlen; Marina Kunstreich; Nicola Gökbuget
Journal:  Hemasphere       Date:  2021-03-09

Review 8.  Recent perspectives on the association between osteonecrosis and bone mineral density decline in childhood acute lymphoblastic leukemia.

Authors:  Jenneke E van Atteveld; Demi Tc de Winter; Rob Pieters; Sebastian Jcmm Neggers; Marry M van den Heuvel-Eibrink
Journal:  Fac Rev       Date:  2021-06-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.